

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated.

Technology appraisals 71
 ICB commissioned 17
 Non-ICB commissioned 31
 Not applicable 23
 ICB commissioned and approved 16 (94%)
 Average days to compliance 67

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) [TA879]	Terminated appraisal	06/04/2023	TA					N/A	Terminated appraisal
Tezepelumab for treating severe asthma [TA880]	Recommended	20/04/2023	TA	19/07/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments [TA881]	Not recommended	03/05/2023	TA					N/A	Not recommended
Voclosporin with mycophenolate mofetil for treating lupus nephritis [TA882]	Recommended	03/05/2023	TA	01/08/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma [TA883]	Not recommended	03/05/2023	TA					N/A	Not recommended
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal) [TA884]	Terminated appraisal	03/05/2023	TA					N/A	Terminated appraisal
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer [TA885]	Recommended	03/05/2023	TA	01/08/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy [TA886]	Recommended	10/05/2023	TA	08/08/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer [TA887]	Recommended	10/05/2023	TA	08/08/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal) [TA889]	Terminated appraisal	17/05/2023	TA					N/A	Terminated appraisal
Difelikefalin for treating pruritus in people having haemodialysis [TA890]	Recommended	17/05/2023	TA	15/08/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia [TA891]	Recommended	31/05/2023	TA	29/08/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Mosunetuzumab for treating relapsed or refractory follicular lymphoma [TA892]	Not recommended	31/05/2023	TA					N/A	Not recommended
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma [TA897]	Recommended	06/06/2023	TA	04/09/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal) [TA899]	Terminated appraisal	06/06/2023	TA					N/A	Terminated appraisal
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over [TA893]	Recommended	07/06/2023	TA	05/09/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts. CDF.	NHS England
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma [TA894]	Not recommended	07/06/2023	TA					N/A	Not recommended
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy [TA895]	Recommended	07/06/2023	TA	05/09/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts. CDF.	NHS England
Bulevirtide for treating chronic hepatitis D [TA896]	Recommended	07/06/2023	TA	05/09/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer [TA898]	Recommended	14/06/2023	TA	12/09/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Tixagevimab plus cilgavimab for preventing COVID-19 [TA900]	Not recommended	14/06/2023	TA					N/A	Not recommended
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) [TA901]	Terminated appraisal	20/06/2023	TA					N/A	Terminated appraisal
Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction [TA902]	Recommended	21/06/2023	TA	19/09/2023	ICB	19/09/2023	90	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Amber recommended statement
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer [TA903]	Recommended	21/06/2023	TA	19/09/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer [TA904]	Recommended	21/06/2023	TA	19/09/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Upadacitinib for previously treated moderately to severely active Crohn's disease [TA905]	Recommended	21/06/2023	TA (Cost comparison)	21/07/2023	ICB	18/07/2023	27	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red statement
Deucravacitinib for treating moderate to severe plaque psoriasis [TA907]	Recommended	28/06/2023	TA	26/09/2023	ICB	19/09/2023	83	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red statement
Rimegepant for preventing migraine [TA906]	Recommended	05/07/2023	TA	03/10/2023	ICB	19/09/2023	76	Rimegepant is commissioned by integrated care boards. Providers are NHS hospital trusts or primary care practitioners, possibly with	Amber retained statement
Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy [TA908]	Recommended	05/07/2023	TA	03/10/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer [TA909]	Not recommended	12/07/2023	TA					N/A	Not recommended
Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) [TA910]	Terminated appraisal	13/07/2023	TA					N/A	Terminated appraisal
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer [TA911]	Recommended	26/07/2023	TA	24/10/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts. The resource impact of selpercatinib will be covered by the Cancer Drugs Fund budget.	NHS England
Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease [TA912]	Recommended	15/08/2023	TA	13/11/2023	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Risankizumab for previously treated moderately to severely active Crohn's disease [TA888]	Recommended	21/08/2023	TA (EAMS)	20/09/2023	ICB	19/09/2023	29	Commissioned by ICBs for adults and by NHS England for people aged 16 to 17 years. 30-day implementation period	Red statement. TA published 17/05/2023 but 30-day
Semaglutide for managing overweight and obesity [TA875]	Recommended	04/09/2023	TA	03/12/2023	ICB	30/11/2023	87	Commercial availability of product confirmed by company on 04 September 2023. NICE subsequently updated the TA	Red statement
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy [TA913]	Recommended	06/09/2023	TA	05/12/2023	Non-ICB			This technology is commissioned by NHS England. Providers are specialist cardiac centres.	NHS England
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency [TA914]	Recommended	20/09/2023	TA	19/12/2023	Non-ICB			Pembrolizumab is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
Pegunigalsidase alfa for treating Fabry disease [TA915]	Recommended	04/10/2023	TA	02/01/2024	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Bimekizumab for treating active psoriatic arthritis [TA916]	Recommended	04/10/2023	TA (Cost comparison)	03/11/2023	ICB	18/12/2023	75	Bimekizumab is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG
Bimekizumab for treating axial spondyloarthritis [TA918]	Recommended	11/10/2023	TA (Cost comparison)	10/11/2023	ICB	18/12/2023	68	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red statement
Rimegepant for treating migraine [TA919]	Recommended	18/10/2023	TA	16/01/2024	ICB	18/12/2023	61	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts or primary care practitioners.	Temporary amber recommended statement
Tofacitinib for treating active ankylosing spondylitis [TA920]	Recommended	18/10/2023	TA (Cost comparison)	17/11/2023	ICB	18/12/2023	61	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG
Ruxolitinib for treating polycythaemia vera [TA921]	Recommended	18/10/2023	TA	16/01/2024	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Daridorexant for treating long-term insomnia [TA922]	Recommended	18/10/2023	TA	16/01/2024	ICB	23/01/2024	97	This technology is commissioned by integrated care boards. Providers are NHS primary care services,	Green statement
Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal) [TA923]	Terminated appraisal	18/10/2023	TA					N/A	Terminated appraisal
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [TA917]	Recommended	25/10/2023	TA	23/01/2024	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Tirzepatide for treating type 2 diabetes [TA924]	Recommended	25/10/2023	TA	23/01/2024	ICB	23/01/2024	90	This technology is commissioned by integrated care boards. Providers are primary care.	Green statement
Mirikizumab for treating moderately to severely active ulcerative colitis [TA925]	Recommended	25/10/2023	TA (Cost comparison)	24/11/2023	ICB	18/12/2023	54	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG
Baricitinib for treating severe alopecia areata [TA926]	Not recommended	25/10/2023	TA					N/A	Black RAG
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments [TA927]	Recommended	25/10/2023	TA	23/01/2024	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine [TA928]	Not recommended	01/11/2023	TA					N/A	Not recommended
Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction [TA929]	Recommended	01/11/2023	TA (Cost comparison)	01/12/2023	ICB	14/12/2023	43	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts and primary care.	Amber recommended statement
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments [TA930]	Not recommended	15/11/2023	TA					N/A	Not recommended
Zanubrutinib for treating chronic lymphocytic leukaemia [TA931]	Recommended	22/11/2023	TA	20/02/2024	Non-ICB			The technology is commissioned by NHS England.	NHS England
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal) [TA932]	Terminated appraisal	23/11/2023	TA					N/A	Terminated appraisal
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal) [TA933]	Terminated appraisal	29/11/2023	TA					N/A	Terminated appraisal
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal) [TA936]	Terminated appraisal	30/11/2023	TA					N/A	Terminated appraisal
Secukinumab for treating moderate to severe hidradenitis suppurativa [TA935]	Recommended	06/12/2023	TA	05/03/2024	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal) [TA938]	Terminated appraisal	07/12/2023	TA					N/A	Terminated appraisal
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer [TA939]	Recommended	13/12/2023	TA	12/03/2024	Non-ICB			Pembrolizumab plus chemotherapy is commissioned by NHS England, providers are NHS hospital trusts.	NHS England
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes [TA943]	Recommended	19/12/2023	TA	18/03/2024	ICB			Integrated care boards	Red statement
Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms [TA934]	Recommended	20/12/2023	TA	19/03/2024	Non-ICB			Foslevodopa–foscarbidopa is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Targeted-release budesonide for treating primary IgA nephropathy [TA937]	Recommended	20/12/2023	TA	19/03/2024	ICB	27/02/2024	69	This technology is for adults with primary IgAN and is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
Ravulizumab for treating generalised myasthenia gravis (terminated appraisal) [TA940]	Terminated appraisal	20/12/2023	TA					N/A	Terminated appraisal
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal) [TA941]	Terminated appraisal	20/12/2023	TA					N/A	Terminated appraisal
Empagliflozin for treating chronic kidney disease [TA942]	Recommended	20/12/2023	TA	19/03/2024	ICB	22/02/2024	64	This technology is commissioned by integrated care systems/ clinical commissioning groups. Providers are primary care services, NHS hospital trusts and tertiary care services.	Green statement
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer [TA944]	Recommended	10/01/2024	TA	09/04/2024	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer [TA946]	Recommended	17/01/2024	TA	16/04/2024	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Treoosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) [TA945]	Not recommended	30/01/2024	TA					N/A	Not recommended
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments [TA947]	Recommended	31/01/2024	TA	30/04/2024	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments [TA948]	Recommended	31/01/2024	TA	30/04/2024	Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England